MAR | Annual report 2017


Today, Monday April 23, Acarix is publishing its Annual Report for 2017.

For further information please contact:
Christian Lindholm, Interim CEO
Phone: +46 705 118333

This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU
Market Abuse Regulation 596/2014. The information was submitted for publication, through the
agency of the contact person set out above, at 08:00 CET on 23 April 2018.

Notes to editors:
Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and
SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First
North Premier in 2016 and has attracted a highly-experienced management team.
The Acarix CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flow
and myocardial movement with advanced algorithms in a portable device to provide a patientspecific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes. The system has been clinically validated.

Acarix publishes the annual report for 2017

Annual report for 2017

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit